Patients with Uveal Melanoma Tested with DecisionDx®-UM Report Gaining Value from Test Results In Study

WASHINGTON, DC (June 23, 2022) – The Melanoma Research Foundation’s (MRF) CURE OM initiative, dedicated to increasing awareness, education and research funding for ocular melanoma, and Castle Biosciences, a company improving health through innovative tests that guide patient care, announce results of a study assessing patient attitudes towards prognostic testing, particularly with respect to DecisionDx-UM^®. The research indicates that most newly diagnosed uveal melanoma patients desire prognostic information at diagnosis, and that molecular prognostic testing provides considerable value to patients.

For more highlights from the study and additional information, view the Castle Biosciences press release.